AGI reports Phase II IBS, dyspepsia data

AGI reported preliminary results from double-blind Phase II trials of two products: arverapamil (AGI-003) and espindolol (AGI-001). Arverapamil met the primary endpoints of patient global impression and relief of abdominal pain/discomfort but missed the third primary endpoint of use of rescue medication in a trial to treat non-constipation predominant irritable bowel syndrome in 129 patients. Using an intent-to-treat analysis, patients given arverapamil had a response rate of 56.9% based on patient global impression vs. 37.5% for placebo. Those given the R-isomer of verapamil had a response rate of 56.9% based on relief of abdominal pain/discomfort vs. 43.8% with placebo. ...